Enhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670
Open Access
- 1 September 1995
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 116 (2) , 1718-1719
- https://doi.org/10.1111/j.1476-5381.1995.tb16652.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670Hypertension, 1995
- ENDOTHELINS - MOLECULAR-BIOLOGY, BIOCHEMISTRY, PHARMACOLOGY, PHYSIOLOGY, AND PATHOPHYSIOLOGY1994
- SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.Proceedings of the National Academy of Sciences, 1994
- Regional haemodynamic responses to acetylcholine, methoxamine, salbutamol and bradykinin during lipopolysaccharide infusion in conscious ratsBritish Journal of Pharmacology, 1994
- Effects of bosentan (Ro 47–0203), an ETA‐, ETB‐receptor antagonist, on regional haemodynamic responses to endothelins in conscious ratsBritish Journal of Pharmacology, 1994
- Modulation of Circulating Endothelin Levels in Hypertension and Endotoxemia in RatsJournal of Cardiovascular Pharmacology, 1991
- Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassayBiochemical and Biophysical Research Communications, 1989